2026年11月3日星期二
M
Atlante Universale
Notizie flash globali
Vietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Fonte Nature 医学研究4 giorni fa
Sintesi del contenuto

Questo sito fornisce solo titoli e indici di riepilogo; il contenuto completo e i diritti d'autore appartengono all'editore originale. Clicca sul link all'articolo originale per leggerlo.

Vai all'articolo originale
Canale di appartenenza
Salute
Regione di appartenenza
Prospettiva globale
Lingua originale
English
Numero di voce
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Atlante Universale